H.R. 1117 · 119th Congress (2025–2027)
Responsibility in Drug Advertising Act of 2025
This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media.
Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources.
The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 1117’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Rosa L. DeLauro (D-CT-3)
- Policy area
- Health
- Subjects
- Broadcasting, cable, digital technologies
- Drug safety, medical device, and laboratory regulation
- Internet, web applications, social media
- Marketing and advertising
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Responsibility in Drug Advertising Act of 2025
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.
Official title · Introduced in House